RxDoctor Payments Data

Paul Chang, MD

Internal Medicine · Buena Park, CANPI 1487627261

Payments from drug & device makers

$51,185in general payments, 2019–2025

Across 1,352 payments — averaging $37.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$28K
  • AbbVie$3K
  • Amgen$3K
  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • Johnson & Johnson$1K
  • plus $13K from 50 others

What the payments were for

  • Speaking & faculty fees$25,44050%
  • Travel & lodging$4471%
  • Food & beverage$25,18349%
  • Education$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,185 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$215,949
Medicare patients
379
Services billed
2,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin737$625,706
CreonLipase/Protease/Amylase493$584,214
VascepaIcosapent Ethyl925$430,195
FarxigaDapagliflozin Propanediol478$369,950
JanuviaSitagliptin Phosphate329$262,268
EliquisApixaban286$207,286
ProliaDenosumab122$201,957
LinzessLinaclotide311$193,393
VemlidyTenofovir Alafenamide134$185,874
OzempicSemaglutide148$149,791
ZtlidoLidocaine186$142,892
TradjentaLinagliptin178$119,315
ZenpepLipase/Protease/Amylase69$78,466
Evenity (2 Syringes)Romosozumab-Aqqg33$76,945
JanumetSitagliptin Phos/Metformin Hcl92$60,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$2,814$791,884820 claims
Boehringer IngelheimJardiance, Tradjenta$1,617$745,022915 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,531$396,481515 claims
MerckJanuvia, Janumet$567$322,331421 claims
AmgenProlia, Evenity (2 Syringes), Evenity$2,629$315,313168 claims
PfizerEliquis$1,037$207,286286 claims
GileadVemlidy$28,075$185,874134 claims
Novo NordiskOzempic$1,060$149,791148 claims
Scilex Pharmaceuticals Inc.Ztlido$680$142,892186 claims
Aimmune Therapeutics, Inc.Zenpep$57$78,46669 claims
GSKTrelegy Ellipta, Breo Ellipta$737$74,862103 claims
BayerKerendia$774$55,12154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Buena Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →